Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Application
Item No. 24621

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
C16 Glucosylceramide-d3 is intended for use as an internal standard for the quantification of C16 glucosylceramide by GC- or LC-MS. C16 glucosylceramide is an endogenous bioactive sphingolipid.1,2 It is a precursor in the synthesis of C16 lactosylceramide (Item No. 24352) that is formed via metabolism of C16 ceramide (Item No. 10681) by glucosylceramide synthase.3 Inhalation of C16 glucosylceramide reduces lung colonization by P. aeruginosa and increases survival in a mouse model of cystic fibrosis.1 C16 Glucosylceramide levels are elevated in the plasma of Parkinson's disease patients with cognitive impairments.2 As this product is derived from a natural source, there may be variations in the sphingoid backbone. [Matreya, LLC. Catalog No. 1533]
WARNING This product is not for human or veterinary use.
1. Glucosylceramide critically contributes to the host defense of cystic fibrosis lungs. Cell Physiol. Biochem. 41(3), 1208-1218 (2017).
2. Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson’s disease and associated with cognitive impairment: A pilot study. PLoS One 8(9), e73094 (2013).
3. Sphingolipids, insulin resistance, and metabolic disease: New insights from in vivo manipulation of sphingolipid metabolism. Endocr. Rev. 29(4), 381-402 (2008).
Acid ceramidase ASAH1 is a key regulator of epidermal ceramide levels and composition. The Journal of Biological Chemisty 302(3), 111178 (2026).